Georgia Life Sciences Names 2025 Golden Helix Award Winners

Academic Innovators and Industry Leaders to be Honored at the Georgia Life Sciences Summit 

August 12, 2025 - The Georgia Life Sciences Golden Helix Awards celebrate excellence and achievement across Georgia’s life sciences ecosystem, recognizing the individuals, companies, and institutions making significant contributions to scientific discovery, health innovation, and economic growth in the state and beyond. 


This year’s winners will be honored at the welcome reception and awards ceremony on day one of the Georgia Life Sciences Summit, August 26-27 at the Sandy Springs Performing Arts Center.


We are pleased to announce this year’s slate of 2025 Golden Helix Award winners: 


PHOENIX AWARD: Boehringer-Ingelheim / University of Georgia  for the Sustainable Development Excellence Certificate Program 

This award, sponsored by the Metro Atlanta Chamber, celebrates an industry/academic collaboration, or other allied partnership, that demonstrate strength, tenacity, and leadership. Like the mythical phoenix, together they exemplify how strategic partnerships can accelerate discovery, fuel commercialization, and create meaningful impact for patients and communities. 


INNOVATION AWARD: Myomatrix

Presented to an institution, team, or individual whose innovation goes beyond the traditional paradigms and has the potential to significantly impact human health, agriculture, or environmental sustainability. Eligible innovations may include—but are not limited to—advancements in biotechnology, pharmaceuticals, diagnostics, medical devices, digital health, or life science-related AI and data platforms. 


DEAL OF THE YEAR AWARD

  • Andson Biotech (Private Financing), biotools company revolutionizing sample preparation for mass spectrometry workflows, for closing a $3.6M seed round led by industry veterans and expanding from three to ten employees while launching its DynaChip X1 platform into commercial markets. 
  • Micron Biomedical (Private Financing), for securing $16M to expand manufacturing of its needle-free vaccine delivery technology and advance multiple vaccine candidates toward commercialization.
  • Moonlight Therapeutics (Private Financing), or closing its first equity round, Series A, co-led by Portal Innovations, to advance its novel intradermal allergen immunotherapy platform for treating food allergies, beginning with MOON101 for peanut allergy.
  • Synaptrix (Private Financing), a medical device company developing the groundbreaking NOVABLOC™ system for drug-free postoperative pain management, for raising $13M in Series A funding led by Hatteras Venture Partners to support pivotal studies, regulatory submission, and commercialization.
  • ANI Pharmaceuticals (Acquisition) for its definitive agreement to acquire Alimera Sciences, for $453M, expanding its global footprint and portfolio to three commercial rare disease assets.
  • Stryker (Acquisition), for its definitive agreement to acquire Artelon, expanding its portfolio of soft tissue fixation solutions for orthopedic surgeons.
  • Duracell (Economic Development), for selecting Georgia as the site of its new North American R&D headquarters, further strengthening the state’s life sciences and advanced manufacturing ecosystem. 

Presented to a company or institution who has made the most significant transaction of the year (between January 1, 2024-March 31, 2025), a deal that exemplifies strategic vision, market influence, and long-term value creation. Whether it’s a transformative partnership, acquisition, licensing agreement, IPO, or major funding round, this deal represents a defining moment for the companies involved and a milestone for the state’s biotech ecosystem.  

 

COMMUNITY AWARD:

  • ARCS Foundation – Atlanta
  • Jeffrey Gray, Founder and CEO, AgeTech Atlanta
  • Christopher Kunney, Managing Partner and Digital Transformation Strategist, IOTech Consulting, LLC
  • Lisa Middleton, Ph.D., Director, Scientific Affairs, Georgia Cancer Center/Augusta University

Presented to a life sciences organization or individual that has demonstrated continuous commitment to making a positive, lasting impact on their local community. This award recognizes organizations/ individuals that go beyond their day-to-day operations through career development initiatives, outreach programs, patient advocacy, corporate philanthropy, or other significant community contribution.

 

EMERGING LEADER OF THE YEAR AWARD: Benjamin Siciliano, PhD, Radyus Research 

Presented to an individual in the first decade of their career whose achievements are significantly contributing to or transforming the life sciences industry. 


TEACHER OF THE YEAR AWARD: Amanda Barrett, Marietta High School 

Presented to a Georgia biotechnology high school teacher who exhibits innovative teaching, mentorship, and unwavering dedication to inspire the next generation of thinkers, problem-solvers, and future leaders in STEM/ biotechnology.


LEGISLATOR OF THE YEAR AWARD: Senator Chuck Hufstetler, 52nd District, Rome

Honors select legislators in recognition of their leadership in advancing federal and state policies to promote life sciences research, investment, and innovation. 


Winners are selected by the Golden Helix Awards Committee, a select group of leaders from Georgia’s life sciences, academic, and business communities who are responsible for identifying and recommending the most impactful individuals, companies, and organizations for recognition at the Golden Helix Awards. The committee reviews nominations across categories including scientific advancement, public policy, entrepreneurship, education, and community impact, aligning with the mission of the Golden Helix Awards to honor those whose ideas and achievements are leading the way in health and science.


To register for the summit, click here.

August 21, 2026
Genetic Engineering & Biotechnology News (GEN) has named Georgia #4 among its “Next 5 States” for emerging U.S. biopharma clusters . The article highlights UCB’s planned $2 billion investment at in Gwinnett County, Micron Biomedical’s new Alpharetta facility, Manus Bio’s expansion in Augusta, Science Square, Emory University, the CDC — and Georgia Life Sciences’ 10-year Life Sciences Roadmap . This recognition is exciting. But even more importantly, it validates the work happening across our entire ecosystem — and perfect momentum as we head into the 2026 Georgia Life Sciences Summit next week. Read more by visiting: Next 10 U.S. Biopharma Clusters
August 17, 2026
Biotechnology Innovation Organization (BIO) Senior Vice President of Science & Regulatory Affairs Annetta Beauregard issued the following statement on the release of the Prescription Drug User Fee Act (PDUFA) VIII commitment letter: “For more than 30 years, PDUFA has helped deliver hundreds of new medicines to American patients. As a lead industry negotiator for the PDUFA VIII agreement, BIO supports the PDUFA VIII commitment letter and its strengthening of regulatory review, advancing innovation, and helping deliver safe and effective treatments to patients. “Specifically, the PDUFA VIII agreement includes important commitments that bolster the FDA’s core review activities, ensure accountability for predictable performance, improve financial sustainability and improve communication, transparency and efficiency. “Timely, bipartisan reauthorization of PDUFA is vital for protecting the health of Americans, strengthening U.S. competitiveness, and maintaining America’s global leadership in medical innovation. BIO is committed to working with Congress to ensure reauthorization by September 30, 2027.” The FDA has announced plans to hold a hybrid public meeting at 9am on 9/16 to discuss the proposed enhancements for the reauthorization of PDUFA for fiscal years (FYs) 2028 through 2033. Learn More about PDUFA and the PDUFA VIII commitment letter HERE .
August 17, 2026
Representing Georgia’s life sciences community, GLS emphasized the importance of advancing policies that improve affordability and patient access while preserving the environment necessary for continued biomedical innovation. In its comments, GLS urged CMS to maintain a framework grounded in FDA regulatory determinations and raised concerns about how certain proposed policies could affect post-approval research and development, investment in new indications, and patient access to innovative therapies. GLS also encouraged CMS to consider the broader implications for healthcare delivery, including the potential impact on patients and providers in rural and underserved communities. As federal drug pricing policy continues to evolve, Georgia Life Sciences will continue to advocate for approaches that balance affordability, access, and innovation while ensuring Georgia’s life sciences community has a voice in the policymaking process. Read Georgia Life Sciences’ full comments to CMS ( click here ).
MORE POSTS